Table 1 Clinical characteristics

From: Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study

Characteristics

Patients, n (%)

No. patients

121

Age, median years

70

Range

49–87

Sex

 Male

94 (77.6)

 Female

27 (22.4)

Clinical stage

 IIIB

26 (21.5)

 IV

95 (78.5)

ECOG PS

 0

48 (39.7)

 1

64 (52.9)

 2

9 (7.4)

Histology

 Adenocarcinoma

28 (23.1)

 Epidermoid

75 (62.0)

 Large cells

18 (14.9)

Therapy

 CDDP-Gem

48 (39.7)

 CBDCA-Gem

73 (60.3)

  1. CDDP cisplatin, CBDCA carboplatin, GEM gemcitabine, ECOG Eastern Cooperative Oncology Group, PS performance status
Back to article page